Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inotiv, Inc. filings document the regulatory record of an operating contract research organization with Discovery and Safety Assessment and Research Models and Services operations. Current reports furnish financial results and business updates, including segment-related discussion for nonclinical and analytical drug development services, research models, and related products.
Material-event filings also describe credit-agreement administration, including waivers tied to minimum liquidity covenants, Nasdaq listing-compliance notices, shareholder voting matters, and governance disclosures. The filings provide formal records of capital-structure obligations, operating results, risk-related events, and public-company compliance matters for NOTV common stock.
Inotiv, Inc. reported that on December 31, 2025 it received a written notice from Nasdaq that its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days. The notice does not immediately affect the listing or trading of the common shares on Nasdaq.
Inotiv has 180 calendar days, until June 29, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least 10 consecutive business days, subject to Nasdaq’s discretion to require a longer period. If it fails to do so, the company may be eligible for an additional 180-day grace period. Inotiv plans to monitor its share price and evaluate options, but there is no assurance it will regain or maintain compliance with Nasdaq listing requirements.
Inotiv, Inc. (NOTV) announced that it has issued a press release with select preliminary unaudited financial results for its fourth quarter and fiscal year ended September 30, 2025. These early figures are being shared ahead of final audited results to give the market an initial view of the company’s recent performance.
The company also disclosed that President and CEO Robert Leasure, Jr. will present at the Jefferies Global Healthcare Conference on November 18, 2025 at 6:00 a.m. Eastern time. A live webcast and replay of this presentation will be available through the Investors section of Inotiv’s website. The press release containing the preliminary results is furnished as Exhibit 99.1.
Inotiv (NOTV): Director Form 4 filing — Director R. Matthew Neff reported selling 2,000 shares of common stock on 11/03/2025 at a weighted average price of $1.2434 per share, with individual sale prices ranging from $1.2100 to $1.2900. The transaction was executed under a Rule 10b5-1 trading plan adopted on 02/13/2025 to cover tax obligations tied to prior equity award vesting. Following the sale, he beneficially owns 153,102 shares directly.
Inotiv, Inc. (NOTV) reported an insider transaction. Director R. Matthew Neff exercised a stock option and acquired 10,000 shares of common stock at $1.94 per share on 10/24/2025 (Transaction Code M). Following the transaction, he directly beneficially owns 155,102 common shares. The exercised derivative was a director stock option covering 10,000 underlying shares, which now has 0 remaining after the exercise; the option carried an expiration date of 10/27/2025.
R. Matthew Neff, a director of Inotiv, Inc. (Ticker: NOTV), reported the sale of 2,000 shares of common stock on 10/01/2025 at a weighted average price of $1.4289 per share. The filing shows 145,102 shares remain beneficially owned by Mr. Neff after the reported sale.
The filing states the sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on February 13, 2025, and that the reported price is the weighted average of multiple sales that ranged from $1.4100 to $1.4650 per share. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Neff.
Inotiv, Inc. has agreed to a proposed settlement of a federal securities class action, including a cash payment of $8,750,000 to investors who bought shares between September 2021 and May 2022 or voted on its Envigo acquisition, which it expects to fund through insurance. The company also reached an agreement in principle to settle two shareholder derivative lawsuits, under which it will adopt governance measures for at least five years such as separating the CEO and board chair roles, keeping an independent chair, strengthening M&A due‑diligence guidelines, and maintaining a disclosure committee.
The derivative settlement credits $2,490,000 of insurance proceeds that will help fund the securities settlement, and plaintiffs may seek up to $2,250,000 in fees, also expected from insurance. Inotiv had recorded a $10.0 million liability and matching receivable for these matters and plans to increase both to $11.0 million as of September 30, 2025. Separately, a 2025 cybersecurity incident has triggered three privacy class actions and caused ongoing operational disruptions, with full business and financial impacts still under evaluation. Inotiv has engaged Perella Weinberg Partners to advise on potential debt refinancing alternatives.
Inotiv, Inc. (NOTV) director R. Matthew Neff sold 2,000 shares of common stock on 09/02/2025 under a pre-established Rule 10b5-1 trading plan. The reported weighted average sale price was $1.6688 per share, with individual sale prices ranging from $1.6550 to $1.6900. After the transactions, Neff beneficially owns 147,102 shares. The Form 4 was signed by Beth Taylor as attorney-in-fact on 09/04/2025 and includes an undertaking to provide per-price sale detail to regulators or holders upon request.
Inotiv, Inc. (NOTV) Form 144 reports a proposed sale of 6,000 common shares through The Charles Schwab Corporation with an aggregate market value of $10,000. The filing lists 34,354,251 shares outstanding and an approximate sale date of 09/02/2025. The shares were acquired as restricted stock that vested on 04/01/2023. The filing also discloses prior sales by the same person of 2,000 shares on 07/01/2025 (gross proceeds $3,620) and 2,000 shares on 08/01/2025 (gross proceeds $3,818). The signer represents they have no undisclosed material nonpublic information.
Inotiv, Inc. (NASDAQ: NOTV) is filing an S-3 shelf prospectus to permit future offerings of securities, including an at-the-market equity program managed by Jefferies. The company describes two operating segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS), which together provide nonclinical drug development services and research animals/products to pharmaceutical, device, academic and government clients. The prospectus states net proceeds are expected to be used for working capital and general corporate purposes, and sales may occur from time to time at varying prices under a sales agreement with Jefferies that pays up to 3.0% commission. The registrant discloses an auditor’s report from Ernst & Young LLP that includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern and notes material weaknesses in internal control over financial reporting. The filing warns investors of immediate dilution risk, variability of proceeds from ATM sales, and typical forward-looking statement cautions.
Inotiv, Inc. reported that on August 8, 2025 it discovered a cybersecurity incident in which a threat actor gained unauthorized access to and encrypted certain company systems. In response, Inotiv launched an investigation, engaged external cybersecurity specialists, restricted access to affected systems, and notified law enforcement.
The incident has disrupted parts of Inotiv’s business operations by limiting access to portions of its networks, internal data storage, and some internal business applications. The company has activated its business continuity plan, shifting some work to offline alternatives while it works to restore systems, though the timeline for full restoration is not yet known. The investigation is ongoing, and Inotiv states that the full scope, nature, and operational and financial impacts are not yet known, and it has not determined whether the incident is reasonably likely to have a material impact.